# Trae Review: Phase A Product Canon

**Date**: 2026-01-29
**Reviewer**: Trae (Independent Auditor)
**Verdict**: APPROVE

## 1. Executive Summary
Re-review confirms the previously execution-blocking canon contradictions have been resolved: the Year 1/2/3 mapping is now explicit and consistent, Multi-CRM sequencing aligns to 2028+, and the Year 1 “marketplace” scope is clarified as curated (not user-submitted). Audit log semantics are now coherent across PRD and System Architecture (append-only + long-term audit retention + separate execution log retention). Remaining issues are non-blocking documentation hygiene and external-facing credibility items.

Reviewed artifacts:
- Prior review: `COCKPIT/artifacts/TRAE_REVIEW/REVIEW_PHASE_A.md`
- Response summary: `COCKPIT/artifacts/TRAE_REVIEW/RESPONSE_TO_REVIEW.md`
- Product Canon: all files under `PRODUCT/`

## 2. Risk Assessment
| Risk | Severity | Mitigation Proposed | Trae Comment |
|------|----------|---------------------|--------------|
| Timeline canon drift reappears in future edits | Medium | Keep a single “Canon Timeline” line in Vision + enforce via review checklist | Explicit canon timeline now present in Vision; keep it authoritative. |
| Marketplace scope creep (curated → user-submitted too early) | Medium | Treat “user-submitted marketplace” as a gated Year 2+ decision | Market Strategy + PRD language now supports curated-only for Year 1. |
| Market sizing used externally without citations | Medium | Require citations before investor-facing use; keep as hypothesis internally | Assumptions registry now labels TAM as uncited hypothesis. |
| Link portability issues if shared outside IDE | Low | Convert to relative links when publishing externally | Known tooling/portability tradeoff; non-blocking for internal execution. |

## 3. Findings & Required Actions
### Critical (Must Fix Before Execution)
- [ ] None identified in this re-review. Previously critical blockers are resolved and canon is execution-safe for internal planning/build.

### Warnings (Proceed with Caution)
- [ ] [Major] Maintain the canonical Year mapping as a single source of truth and prevent regressions. Evidence: `PRODUCT/VISION_CANON.md` declares “Canon Timeline: Year 1 = 2026, Year 2 = 2027, Year 3 = 2028” ([VISION_CANON.md:L121-L138](file:///Users/ranjansingh/Desktop/NeuronX/PRODUCT/VISION_CANON.md#L121-L138)). Action: treat this as authoritative; require any year label changes to update all docs in one patch.

- [ ] [Major] Ensure Multi-CRM remains explicitly sequenced as 2028+ in downstream artifacts (plans/backlog) to avoid roadmap drift. Evidence: PRD roadmap alignment includes “Multi-CRM (2028+)” ([PRD.md:L345-L354](file:///Users/ranjansingh/Desktop/NeuronX/PRODUCT/PRD.md#L345-L354)) and Architecture has “Year 3+ (2028+): Multi-CRM Support” ([SYSTEM_ARCHITECTURE.md:L551-L555](file:///Users/ranjansingh/Desktop/NeuronX/PRODUCT/SYSTEM_ARCHITECTURE.md#L551-L555)). Action: enforce canon compliance in planning templates.

- [ ] [Major] Market sizing should not be used externally until citations are added for core TAM/SAM claims. Evidence: Market Strategy marks TAM as “Hypothesis (uncited directional estimate)” with explicit remediation ([MARKET_STRATEGY.md:L47-L58](file:///Users/ranjansingh/Desktop/NeuronX/PRODUCT/MARKET_STRATEGY.md#L47-L58)). Action: add citations before investor-facing or public use; keep internal as validated hypotheses.

- [ ] [Minor] Link portability remains a known limitation if canon is shared outside the current IDE environment. Evidence: absolute `file:///Users/...` references across canon docs (e.g., [MARKET_STRATEGY.md:L9-L12](file:///Users/ranjansingh/Desktop/NeuronX/PRODUCT/MARKET_STRATEGY.md#L9-L12)). Action: convert to repo-relative links if/when publishing externally.

## 4. Verdict Rationale
APPROVE because all previously execution-blocking contradictions (timeline mapping, Multi-CRM sequencing, marketplace scope) are resolved and audit/retention semantics are now consistent between PRD and System Architecture (append-only + 7-year audit retention + separate execution log retention) ([PRD.md:L296-L303](file:///Users/ranjansingh/Desktop/NeuronX/PRODUCT/PRD.md#L296-L303), [SYSTEM_ARCHITECTURE.md:L496-L500](file:///Users/ranjansingh/Desktop/NeuronX/PRODUCT/SYSTEM_ARCHITECTURE.md#L496-L500)). Remaining items are non-blocking and are explicitly framed as cautions/hygiene for external sharing and credibility.
